Cargando…

Whole Genome Amplification of DNA for Genotyping Pharmacogenetics Candidate Genes

Whole genome amplification (WGA) technologies can be used to amplify genomic DNA when only small amounts of DNA are available. The Multiple Displacement Amplification Phi polymerase based amplification has been shown to accurately amplify DNA for a variety of genotyping assays; however, it has not b...

Descripción completa

Detalles Bibliográficos
Autores principales:	Philips, Santosh, Rae, James M., Oesterreich, Steffi, Hayes, Daniel F., Stearns, Vered, Henry, N. Lynn, Storniolo, Anna M., Flockhart, David A., Skaar, Todd C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Research Foundation 2012
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3315790/ https://www.ncbi.nlm.nih.gov/pubmed/22479249 http://dx.doi.org/10.3389/fphar.2012.00054

Ejemplares similares

CYP2D6 genotype and tamoxifen response
por: Rae, James M, et al.
Publicado: (2005)

Polymorphisms in drug-metabolizing enzymes and steady-state exemestane concentration in post-menopausal patients with breast cancer
por: Hertz, Daniel L., et al.
Publicado: (2016)

Lack of association between oestrogen receptor polymorphisms and change in bone mineral density with tamoxifen therapy
por: Henry, N L, et al.
Publicado: (2010)

Patient-Reported Outcomes and Early Discontinuation in Aromatase Inhibitor-Treated Postmenopausal Women With Early Stage Breast Cancer
por: Kadakia, Kunal C., et al.
Publicado: (2016)

Nephrotoxicity in a Patient With Inadequate Pain Control: Potential Role of Pharmacogenetic Testing for Cytochrome P450 2D6 and Apolipoprotein L1
por: Tillman, Emma M., et al.
Publicado: (2020)

The role of single nucleotide polymorphisms in breast cancer metastasis
por: Rae, James M, et al.
Publicado: (2008)

Aromatase inhibitor-induced modulation of breast density: clinical and genetic effects
por: Henry, N L, et al.
Publicado: (2013)

Variability Between Clinical Pharmacogenetics Implementation Consortium (CPIC(®)) Guidelines and a Commercial Pharmacogenetics Laboratory in Genotype to Phenotype Interpretations For Patients Utilizing Psychotropics
por: Blazy, Christopher, et al.
Publicado: (2022)

Screening of Novel Pharmacogenetic Candidates for Mercaptopurine-Induced Toxicity in Patients With Acute Lymphoblastic Leukemia
por: Cao, Minyuan, et al.
Publicado: (2020)

Pharmacogenetics in the Brazilian Population
por: Suarez-Kurtz, Guilherme
Publicado: (2010)

Pharmacogenetics of antipsychotic-induced side effects
por: Lencz, Todd, et al.
Publicado: (2009)

Implementing pharmacogenetic testing in fluoropyrimidine-treated cancer patients: DPYD genotyping to guide chemotherapy dosing in Greece
por: Ragia, Georgia, et al.
Publicado: (2023)

Pharmacogenetics – Challenges and Opportunities Ahead
por: Zanger, Ulrich M.
Publicado: (2010)

Pharmacogenetics in Primary Headache Disorders
por: Belyaeva, Irina I., et al.
Publicado: (2022)

Relevance of G-quadruplex structures to pharmacogenetics
por: Cree, Simone L., et al.
Publicado: (2014)

Pharmacogenetics in Psychiatry: An Update on Clinical Usability
por: van Schaik, Ron H. N., et al.
Publicado: (2020)

Editorial: Insights in Pharmacogenetics and Pharmacogenomics: 2021
por: Agúndez, José A. G., et al.
Publicado: (2022)

Warfarin Pharmacogenetics: Challenges and Opportunities for Clinical Translation
por: Limdi, Nita A.
Publicado: (2012)

Pharmacogenetics and Predictive Testing of Drug Hypersensitivity Reactions
por: Böhm, Ruwen, et al.
Publicado: (2016)

Actionable Pharmacogenetic Variation in the Slovenian Genomic Database
por: Hočevar, Keli, et al.
Publicado: (2019)

Clozapine Pharmacogenetic Studies in Schizophrenia: Efficacy and Agranulocytosis
por: Numata, Shusuke, et al.
Publicado: (2018)

Clinical pharmacology and pharmacogenetics of prostaglandin analogues in glaucoma
por: Zhou, Lin, et al.
Publicado: (2022)

Current State and Future Prospects of Direct-to-Consumer Pharmacogenetics
por: Chua, E. W., et al.
Publicado: (2012)

Can pharmacogenetics explain efficacy and safety of cisplatin pharmacotherapy?
por: Roco, Ángela, et al.
Publicado: (2014)

Therapeutic Drug Monitoring and Pharmacogenetic Testing in Northern China
por: Zhang, Chunyan, et al.
Publicado: (2021)

Editorial: The Potential of Machine Learning in Pharmacogenetics, Pharmacogenomics and Pharmacoepidemiology
por: Garcia-Agundez, Augusto, et al.
Publicado: (2022)

Ensuring equity: Pharmacogenetic implementation in rural and tribal communities
por: Leitch, Tianna M., et al.
Publicado: (2022)

Editorial: Brief research reports in pharmacogenetics and pharmacogenomics: 2022
por: Sessa, Francesco, et al.
Publicado: (2023)

Editorial: Editor’s feature: negative findings in pharmacogenetics and pharmacogenomics
por: Agúndez, José A. G., et al.
Publicado: (2023)

Pharmacogenetic aspects of addictive behaviors
por: Hejazi, Nadia S.
Publicado: (2007)

Pharmacogenetics and outcome with antipsychotic drugs
por: Pouget, Jennie G., et al.
Publicado: (2014)

OX(1) and OX(2) orexin/hypocretin receptor pharmacogenetics
por: Thompson, Miles D., et al.
Publicado: (2014)

Pharmacogenetic Variation in Over 100 Genes in Patients Receiving Acenocumarol
por: Gonzalez-Covarrubias, Vanessa, et al.
Publicado: (2017)

Computational Methods for the Pharmacogenetic Interpretation of Next Generation Sequencing Data
por: Zhou, Yitian, et al.
Publicado: (2018)

Pharmacogenetic Testing for Prevention of Severe Cutaneous Adverse Drug Reactions
por: Chang, Chih-Jung, et al.
Publicado: (2020)

Variation in Actionable Pharmacogenetic Markers in Natives and Mestizos From Mexico
por: Gonzalez-Covarrubias, Vanessa, et al.
Publicado: (2019)

Pharmacogenetics and Precision Medicine Approaches for the Improvement of COVID-19 Therapies
por: Biswas, Mohitosh, et al.
Publicado: (2022)

Editorial: Emerging talents in frontiers in pharmacology: pharmacogenetics and pharmacogenomics 2022
por: Klomp, Sylvia D., et al.
Publicado: (2023)

Estradiol as a Targeted, Late-Line Therapy in Metastatic Breast Cancer with Estrogen Receptor Amplification
por: Kota, Karthik, et al.
Publicado: (2017)

Efavirenz-mediated induction of omeprazole metabolism is CYP2C19 genotype-dependent
por: Michaud, Veronique, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_d5867laepjalc2sn7kv0g1jqmh